BioSpace News Archive

ImmuCell Corporation, a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended June 30, 2021 after the market closes on Thursday, August 12, 2021.

Arch Biopartners Inc., a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, provided an update that the analysis of the results of the Phase II trial of its lead drug LSALT peptide is ongoing and will be disclosed to the public following third-party, scientific peer review.

Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended June 30, 2021.

Bio-Techne Corporation reported its financial results for the fourth quarter ended June 30, 2021.

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, announced financial results for the second quarter of 2021 and provided a general business update.

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, reported financial results and provided business updates for the second quarter of fiscal year 2021.

TCR2 Therapeutics Inc., a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, announced financial results for the second quarter ended June 30, 2021 and provided a corporate update.

Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced that its majority-owned company Oravax Medical Inc.'s oral COVID-19 vaccine will be featured in the Keynote Talk at the Arena International Vaccines Virtual Conference 2021 on August 5, 2021, at 9:00 a.m. Eastern.

Merck, known as MSD outside the United States and Canada, announced that the Phase 3 KEYNOTE-716 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, met its primary endpoint of recurrence-free survival for the adjuvant treatment of patients with surgically resected high-risk stage II melanoma.

Madrigal Pharmaceuticals, Inc. reports its second quarter 2021 financial results and provides a summary of corporate accomplishments.